On October 4, Brian Williams continued his "NBC Nightly News" report on the "Largest Medical Device Failure Ever," involving "metal-on-metal" hip replacements manufactured by DePuy, a subsidiary of Johnson and Johnson.
I am 35, female and have elevated levels of uric acid. My doctor wants me tested for gout in my left ankle, but the pain in my ankle didn't start until I began using it to overcompensate for my other injured leg by limping. Will the black cherry concentrate I've heard about in pill form lower the uric acid levels, and how can I tell the difference between gout and tendinitis?
Drugs that treat psoriasis and rheumatoid arthritis, or RA, by suppressing the immune system may also reduce the risk of developing diabetes, at least in people who already have one of these conditions, according to a new study in the Journal of the American Medical Association.
Swiss drug maker Novartis AG is facing tough competition from generics as several of its key drugs -- namely, bestseller Diovan for hypertension -- begin to lose patent protection in 2012.
Drinking too much soda, orange juice, or other sugary drinks appears to increase the risk of developing gout, an especially painful form of arthritis, according to a new study in the Journal of the American Medical Association.
Moderate drinking has been linked to a variety of health benefits, including a reduced risk of heart disease, stroke, and diabetes. According to a new study, drinking alcohol may also ease the pain of -- and lower the risk of developing -- rheumatoid arthritis, a potentially crippling autoimmune disorder.
A simple blood test may allow doctors to identify a debilitating form of arthritis years before any symptoms appear, which may help to stop the disease in its tracks, new research suggests.
updated: Mon Mar 30 2009 12:39:00
Sorting out fact from fiction is important for arthritis sufferers, as CNN's Judy Fortin reports.
The bad economy and downturn in the housing market aren't the only painful things for Realtor Anne Stephens. Her knees, hips and ankles hurt from arthritis.
My wife thinks she is fat. I disagree. I would consider her chubby at most. She has self-esteem issues and confidence issues because of her weight. I would like to help her lose weight to make herself feel better, but the only problem is she has arthritis in her wrists and ankles. So is there any type of workout that will help my wife lose weight but not mess with her arthritis in the process? Thank you.
Nearly one in five people in the U.S. has some form of osteoarthritis. The condition, which can affect joints, can cause severe pain and limit mobility. Arthroscopic surgery is a common form of treatment for OA of the knee, but studies on its effectiveness have shown varying results. A new study finds that arthroscopic surgery may not be the answer for many patients with OA of the knee.
Nearly a million knee surgeries are performed in North America each year to ease the pain of osteoarthritis -- but researchers say the procedure is a sham
The survey of nearly 800,000 people is the first extensive look at the overlap between the two conditions, said Dr. John Klippel, president of the Arthritis Foundation
Doctor's View: A frightened cancer patient inadvertently heard terrible news. Anesthesia erased her memory. It was a snap decision -- and a compassionate one. But was it right?
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
Takeru Kobayashi of Japan, the hot-dog eating champ of New York City's Coney Island, may be out of commission for next week's annual July 4th contest.
The biotech Amgen reported first-quarter earnings Monday that matched expectations, though its revenue fell just short of forecasts.
The moment of truth has come for Arcoxia, Merck's arthritis painkiller intended to replace the withdrawn drug Vioxx.
Abbott Laboratories is trying to get its top-selling blockbuster drug approved for yet another use, which could lead to further sales.
About 21 million adults have osteoarthritis -- the wear-and-tear condition that causes achy joints and may eventually lead to can't-get-up-from-the-sofa pain.
After a rough couple of years dealing with patent expirations and the often frustrating hunt for new products, drug industry executives would love nothing better than an oracle to predict what products in their labs will become the big blockbuster drugs over the next few years.
Merck & Co. won its second courtroom Vioxx victory this week in a product liability trial, Merck said.
Food and Drug Administration advisers voted in favor of approving the Pfizer painkiller Celebrex as an effective treatment of rheumatoid arthritis for children, even though it is not safe.
Merck & Co. said Monday that its arthritis painkiller Arcoxia does not increase the risk of heart attacks, in a study underscoring the difference between this drug and its withdrawn-from-the-market blockbuster Vioxx.
Merck is experimenting with a new arthritis painkiller that could replace Vioxx, the former billion-dollar blockbuster that has proven to be a liability for the company.
Novartis plans to bring a new arthritis painkiller to the U.S. market, but analysts say its similarity to the disgraced drug Vioxx could kill its chances of becoming a billion-dollar blockbuster.
In the nearly two years since Merck pulled its tainted blockbuster Vioxx from the market, Pfizer has enjoyed a monopoly-like market for its own arthritis drug, Celebrex.
Abbott Labs' fast-growing flagship drug Humira is grabbing market share and making money ... and now the company is trying to win the blessings of the FDA to make more.
A federal jury ruled that Eli Lilly & Co. infringed the patent of Ariad Pharmaceuticals with its drugs Evista and Xigris, and ordered the drugmaker to pay the Massachusetts biotech firm $65.2 million, the companies said.
Merck stock tumbled Thursday, a day after the nation's No. 2 drugmaker was found liable for the heart attack of a New Jersey man who took Vioxx and a jury awarded $4.5 million in damages.
Celebrex, an arthritis painkiller from Pfizer, could be used to prevent colorectal cancer, according to studies revealed today by the American Association for Cancer Research.
The FDA's balancing act between safety and speed is taking center stage with the multiple sclerosis drug Tysabri.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
A federal judge declared a mistrial Monday in the latest lawsuit against Merck concerning its painkiller Vioxx, attorneys for both the plaintiff and drugmaker said.
The "art" of medicine -- a term that doctors often fall back on when the "science" of medicine is open to interpretation -- was illustrated by studies in the leading medical journals this week.
An FDA advisory panel voted unanimously in favor of abatacept, a Bristol-Myers Squibb treatment for rheumatoid arthritis, a move that often precedes FDA approval.
Bristol-Myers Squibb faces votes by FDA advisory panels on two key drugs in its pipeline, decisions that could affect the company's financial future for years to come.
The plaintiff in the first of several thousand Vioxx lawsuits took the stand in a Texas court Thursday and said she is taking antidepressants to alleviate the sorrow from her husband's death.
A Texas judge rejected Merck's request to postpone its July 11 court date for the first in a series of lawsuits involving Vioxx, an arthritis painkiller the company withdrew last year because of health risks, according to a court spokesperson.
The Texas Attorney General sued Merck Thursday, accusing the drug company of misrepresenting the safety of arthritis painkiller Vioxx, the attorney general's office said.
The health risks surrounding arthritis painkillers have caused physicians to back away from prescribing Celebrex, rather than propping up sales for the sole remaining cox-2 inhibitor on the market, according to an analyst report.
The black box label is the most potent warning in the Food and Drug Administration's arsenal, but it is not necessarily a death knell for drug sales, analysts say.
Maybe you're Diabetic, or someone close to you is. Or maybe Alzheimer's disease runs in your family. If so, Sam Katz, CEO of WellSpring BioCapital Partners, considers you his target market--a "pass...
A cannabis-based painkiller for sufferers of multiple sclerosis is expected to be in Canadian pharmacies this summer, but whether it appears on U.S. pharmacy shelves is a key question.
The Food and Drug Administration asked Pfizer and other manufacturers to revise their labels to include boxed warnings of potential cardiovascular risks and gastrointestinal bleeding from certain arthritis drugs. The FDA also asked Pfizer to withdraw Bextra from the market. Following is the FDA's statement:
Pfizer Inc. agreed Thursday to change the warning labels on its arthritis drug Celebrex and pull Bextra off the market after regulators expressed concerns about the arthritis medicines' safety. Following is Pfizer's statement:
Pfizer Inc. said Thursday that the Food and Drug Administration asked it to pull its arthritis painkiller Bextra from the market. The following is from the FDA statement:
Pfizer Inc. said Thursday it is pulling its arthritis painkiller Bextra off the market after the Food and Drug Administration asked for the recall.
Two drug candidates that would reduce the symptoms of rheumatoid arthritis have passed testing, announced drug manufacturers Human Genome Sciences, Roche, Genentech and Biogen Idec on Wednesday, offering hope where arthritis treatments have raised health concerns.
A pullback in oil prices Monday combined with strength in the dollar could put stocks in rally mode at the start of a new trading week on Wall Street.
The Food and Drug Administration issued a public health advisory Thursday, recommending doctors limit the use of Pfizer Inc.'s Celebrex and Bextra to patients who can't take other pain medicines.
The Food and Drug Administration issued a warning to users of the over-the-counter pain reliever naproxen Monday after federal researchers found an increased number of heart attacks and strokes among users.
Under pressure from regulators, Pfizer has agreed to limit advertising of Celebrex after a clinical trial showed the painkiller was linked to an increased risk of heart attacks and strokes.
Pfizer Inc., the world's largest drugmaker, said Friday that a study found an increased risk of heart attacks to patients using its popular arthritis drug Celebrex, but the company said it has no plans to pull the painkiller from the market.
With a new study that indicates the nation's leading arthritis painkiller could raise the risk of heart attacks, the Food and Drug Administration advised doctors Friday to consider "alternative therapy" to Celebrex.
Pfizer Inc. said Friday it had no plans to pull the popular painkiller Celebrex off the market despite data showing that patients using the drug in a long-term cancer study had more than double the risk of a heart attack.
The New York State pension fund sued Merck & Co. Tuesday, claiming to have suffered huge financial losses from the scandal surrounding the drugmaker's Vioxx painkiller.
Drug stocks took another hit Friday, a day after a veteran Food and Drug Administration researcher said that five drugs currently on the market needed closer scrutiny for possible safety risks.
The chairman of pharmaceutical heavyweight Merck said Tuesday its arthritis drug Vioxx was pulled from the market at the earliest indication of problems.
Listening to Ray Gilmartin, you can't help but be struck by how matter-of-fact and calm the man seems. The 63-year-old Merck chairman and CEO is soft-spoken, quick with a smile, and unfailingly pol...
Drug manufacturer Pfizer said Friday that its Bextra drug, seen as an alternative to Merck's Vioxx arthritis medication, may raise heart attack risk in high-risk bypass surgery patients.
Johnson & Johnson says its rheumatoid arthritis drug Remicade may put patients at higher risk for lymphoma, and the company is sending out warning letters to physicians.
The Dow tumbled and the broader market was mixed Thursday, as investors struggled to make end-of-quarter moves and dealt with a big setback after Merck withdrew one of its key drugs from the market.
Merck's withdrawal of its arthritis treatment sent the stock tumbling more than 25 percent and pushed the Dow into deeply negative territory at the open Thursday.
Merck & Co. on Thursday recalled its arthritis drug Vioxx after an ongoing trial confirmed the medication increases the risk of heart attack and strokes. The news sent stock down nearly 27 percent and erased $25 billion from its market value.
A common thread connects this year's standouts: They all responded to crisis by radically changing the way they make things. Autoliv reprocessed its factory to fend off stiff competition in airbags...
The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...
When it comes to working out, no exercise regimen is "one size fits all," but one particular martial art form comes pretty close.
For years we've heard that the pharmaceutical sector is the closest we have come to a sure thing in the world of investing. We practically know the arguments by heart. America is aging: We need mor...
In the future, successful drug companies will have to come up with innovative cures for complex, hard-to-treat conditions like cancer -- without letting their research-and-development spending get out of hand.
For years Amgen has seemed biotechnology's best answer to the likes of Merck--a sector leader with so much heft and momentum that you'd recommend its stock to your mom. But now making that analogy ...
On Dec. 17, Amgen, the flagship company of the biotechnology world, closed the biggest merger in the sector's history. It agreed to pay $16 billion to buy rival Immunex, primarily for the right to ...
In a queasy, headachy economy like this one, it's easy to understand why investors would reach for the medicine chest. Pharmaceuticals stocks have shone for decades as growth stalwarts relatively u...
HELP KIDS FIGHT FAT Obesity isn't just a health threat to the middle-aged anymore; today 11% of American kids are overweight, up from 5% 20 years ago. A new weapon in the fight against fat: the fir...
Like all mass hysterias, dot.com dementia induces serious tunnel vision. Witness investors' delayed reaction to the biotech industry's recent winning streak at the FDA. For more than a year the bio...
XIRCOM The connection for remote PC users
As many of America's 23 million arthritis sufferers know all too well, the pills that provide welcome relief from joint pain and inflammation may, over time, also cause stomach trouble, ranging fro...
Everyone who saw me that night--nurses, residents, doctors, technicians, and emergency room attendants--said the same thing: What I was experiencing was the male equivalent of labor pain. I agreed....
One day last March, after rivals Glaxo Wellcome, American Home Products, and others announced they were exploring multibillion-dollar mergers, Pfizer CEO William Steere went to the fitness center i...
For 11 lonely years cell biologist L. David Tomei toiled away in the Columbus labs of Ohio State University, exploring a process known as apoptosis--programmed cell death, in which the body divides...
The Internal Revenue Service and charities are slugging it out again. Nonprofit groups keep launching new money-raising ventures, like this fall's splashy fashion industry T-shirt sale that will be...
PHARMACEUTICAL companies have long had the best deal in American business, a foolproof formula for turning chemical compounds into gold. The industry followed its own set of rules, raising prices a...
A bewildering choice confronts anyone with a garden variety pain like a headache, a stomachache, or a sprained ankle. Are you better off taking aspirin, Motrin IB, Advil, Nuprin, Tylenol, or one of...
EVERY ONCE in a while somebody gets a bright idea that winds up revolutionizing an industry. Martin Wygod did, and now his company, Medco Containment Systems, is turning the $60-billion-a-year phar...
That these are wonderful times for aging neoconservative hypochondriacs with modems was borne out yet again on a recent Sunday morning around 6 A.M. This was when your servant awoke with a swollen,...
MENTION drug companies and you'll most likely think of such household names as Merck, Lilly, Johnson & Johnson, or Bristol-Myers Squibb. But some fresh new players are on the brink of glory. After ...
NO AMERICAN INDUSTRY has ever defied the laws of economic gravity like pharmaceuticals. For the past 30 years the drugmakers of the FORTUNE 500 have enjoyed the fattest profits in big business. The...
BUGS -- viruses and bacteria -- cause most minor diseases, and some of the major ones like AIDS. But many of the real killers and cripplers, including cancer, heart disease, rheumatoid arthritis, a...
CAUTIOUS CLINICAL investigators fear the familiar phrase ''cancer breakthrough'' almost as much as laymen dread the word cancer itself. Surgery, chemicals, and radiation have so far failed to win t...
Loading weather data ...
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|